Incretin-based therapies in hepatology practice

Figure 1 Practical hepatology algorithm for patients receiving or being considered for treatment with a glucagon-like peptide-1 receptor agonist or dual incretin therapy. ¹Red flags include persistently abnormal aminotransferase levels, thrombocytopenia, splenomegaly, and imaging or physical findings suggestive of chronic liver disease or portal hypertension. GLP-1RA: Glucagon-like peptide-1 receptor agonist; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; FIB-4: Fibrosis-4 index; HbA1c: Glycated hemoglobin; ELF: Enhanced Liver Fibrosis test; HCC: Hepatocellular carcinoma; MASH: Metabolic dysfunction-associated steatohepatitis.